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Abstract
Ileal Crohn’s Disease (CD), a chronic small intestinal inflammatory disorder, is characterized by reduced levels of the
antimicrobial peptides DEFA5 (HD-5) and DEFA6 (HD-6). Both of these a-defensins are exclusively produced in Paneth cells
(PCs) at small intestinal crypt bases. Different ileal CD–associated genes including NOD2, ATG16L1, and recently the b-
catenin–dependant Wnt transcription factor TCF7L2 have been linked to impaired PC antimicrobial function. The Wnt
pathway influences gut mucosal homeostasis and PC maturation, besides directly controlling HD-5/6 gene expression. The
herein reported candidate gene study focuses on another crucial Wnt factor, the co-receptor low density lipoprotein receptor-
related protein 6 (LRP6). We analysed exonic single nucleotide polymorphisms (SNPs) in a large cohort (Oxford: n=1,893) and
prospectively tested 2 additional European sample sets (Leuven: n=688, Vienna: n=1,628). We revealed an association of a
non-synonymous SNP (rs2302685; Ile1062Val) with early onset ileal CD (OR 1.8; p=0.00034; for homozygous carriers: OR 4.1;
p=0.00004) and additionally with penetrating ileal CD behaviour (OR 1.3; p=0.00917). In contrast, it was not linked to adult
onset ileal CD, colonic CD, or ulcerative colitis. Since the rare variant is known to impair LRP6 activity, we investigated its role
in patient mucosa. Overall, LRP6 mRNA was diminished in patients independently from the genotype. Analysing the mRNA
levels of PC product in biopsies from genotyped individuals (15 controls, 32 ileal, and 12 exclusively colonic CD), we found
particularly low defensin levels in ileal CD patients who were carrying the variant. In addition, we confirmed a direct
relationship between LRP6 activity and the transcriptional expression of HD-5 using transient transfection. Taken together,
we identified LRP6 as a new candidate gene in ileal CD. Impairments in Wnt signalling and Paneth cell biology seem to
represent pathophysiological hallmarks in small intestinal inflammation and should therefore be considered as interesting
targets for new therapeutic approaches.
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Introduction
Ileal Crohn’s disease (CD) belongs to the group of inflammatory
bowel diseases characterized by chronic intestinal inflammation,
ulceration and consequent diarrhoea [1]. Both, environmental and
inherited factors contribute to the disease risk [2,3] and different
genetic backgrounds likely explain variability in disease severity and
especially disease location. Whereas the behaviour as well as the
severity might change overtime, the disease location remains stable
throughout the course, arguing for different pathogenetic mecha-
nisms in the location specific disease subgroups [4–6]. Supporting
this, genetic associations including NOD2, ATG16L1,a sw e l la s
TCF7L2(alsoknown as TCF4) have been specifically associated with
small intestinal, but not colonic CD [7]. Since bacteria represent the
main target of adaptive immune responses [8–10] and trigger
mucosal inflammation in susceptible individuals [11], we have
suggested that location specific antimicrobial immunity defects
render the mucosa susceptible to microbial adhesion and invasion
[12]. Such defence impairments accommodate both, the inherited
and the microbial component in the pathogenesis [13] and help to
explain the stability of the specific disease locations. In contrast to
colonic CD and ulcerative colitis (UC), ileal CD is characterized by
a specific reduction of two Paneth cell antimicrobial peptides
(AMPs), the human defensins (HD) -5 and -6 [13–16]. These two
Paneth cell a- defensins are the most abundant products of the
specialized secretory cells residing at the base of small intestinal
crypts of Lieberku ¨hn and the most prominent AMPs in the ileal
mucosa [17,18]. They are secreted after activation of pattern
recognition receptors with microbial products, for example with
muramyldipeptide (MDP) [19], the minimal bioactive peptidogly-
can motif common to all bacteria, recognized by NOD2 [20,21].
Paneth cell antimicrobials are involved in the regulation of the
PLoS Genetics | www.plosgenetics.org 1 February 2012 | Volume 8 | Issue 2 | e1002523luminal commensal makeup [15,22] and protect the organism from
pathogens. Different mechanisms leading to diminished PC a-
defensin levels in Crohn’s disease have been identified. In addition
to mutations in the susceptibility gene NOD2, which explain the
decrease in some patients [14,23], alterations in the Wnt pathway
seem to play an important role in the majority of patients with ileal
CD [24,25]. Given that Wnt controls Paneth cell maturation and
intestinalproliferation[26],asidefromdirectlyregulatingHD-5and
-6, the observed link might suggest an involvement of impaired cell
differentiation in the disorder. We first identified a decrease of
TCF7L2 mRNA and subsequently reduced HD-5 promoter
binding activity of mucosal extracts in ileal CD patients [25]. A
following genetic study in a large sample set of 3 western European
cohorts uncovered an association of TCF7L2 promoter region
variants specifically with ileal CD [24]. We now hypothesized that
upstream Wnt factors might also be affected in ileal CD and
represent interesting factors for target gene association studies. One
component with a key position in canonical Wnt signalling
transduction is the low density lipoprotein receptor-related protein
6 (LRP6) [27–29]. This Wnt co-receptor is essential for cytoplas-
matic stabilization of b- catenin which upon entry into the nucleus
binds to factors of the Lymphoid enhancer family (Lef)/TCF family
and activates promoters of target genes including HD-5 and HD-6.
In mice, impeding LRP6 receptor function leads to rapid inhibition
of intestinal epithelial regeneration, loss of proliferative crypts, and
eventual inflammation and architectural degeneration [30]. These
findings formed the rationale to test the hypothesis that LRP6
impairment could predispose to small intestinal inflammation in
human CD patients. Furthermore we aimed to understand the
functionalpathwayandpossiblelinktoPanethcellinnateimmunity.
Results
Distribution of exonic LRP6 SNPs in a western European
Cohort from Oxford
We studied frequency distributions and linkage disequilibria of
all SNPs reported in the NCBI SNPdatabase in the exonic
regions of LRP6 (Figure 1 upper panel). For a first analysis we
used a well-defined cohort from Oxford including almost 2000
DNA samples from healthy controls and IBD patients. We
determined frequencies for 5 of the 12 exonic SNPs described in
the NCBI SNPdb (Figure 1 lower panel). SNPs with a minor
allele frequency (MAF) of 0 in the Oxford samples were either not
previously validated or so far not been found in western
European cohorts. None of the tested SNPs were associated with
CD or UC overall. However, in this first analysis, the coding rare
allele of rs2302685 exhibited an association with a subgroup: an
early disease onset phenotype in ileal CD (odds ratio (OR) 1.524,
95% confidence interval (CI) 0.988 to 2.345, p=0.05511; for
homozygous carriers OR 3.152, 95% CI 1.128 to 8.845,
p=0.02144). Since none of the other analysed SNPs showed
frequency differences between controls and the different analysed
disease groups we focused only on rs2302685 for additional tests.
We also did not find a significant linkage between this variant and
any of the other tested polymorphic SNPs and therefore did not
include them in the analysis of the two additional cohorts
(Figure 1 lower panel).
Association of the coding rs2302685 minor variant
After association of rs2302685 with early onset ileal CD in the
Oxford patients, we prospectively tested if a higher frequency of
this functional variant can also be found in other cohorts.
Consistent with the first analysis in the Oxford cohort (Table 1,
Oxford), subsequent analysis of two large sample sets (Table 1,
Leuven and Vienna) showed the same overall result, whereas the
frequency distributions among the control groups as well as the not
further sub-grouped patients (IBD, CD, UC) were strikingly
similar (MAFs between 18.47 and 20.59%, Table 1 and Table 2).
Combining all tested samples, an association with early onset ileal
CD (diagnosis at ages 17 and younger) (MAF: 29.57%; OR 1.797,
95% CI 1.298 to 2.486, p=0.00034) and penetrating behaviour
(internal fistulae; Montreal classification B3) (MAF: 23.24%; OR
1.296, 95% CI 1.066 to 1.575, p=0.00917) suggests that
Ile1062Val may influence both, disease onset and severity
(Table 2, Figure 2), even though statistical significance of the
latter association was lost after adjusting for multiple testing
(Bonferroni adjustment for penetrating ileal CD behaviour:
p=0.10087). Gender on the other hand had no impact on the
allele distribution (Table 2). The homozygous genotype of the
minor allele displayed the highest risk for early onset ileal disease
underlining a potential dose effect of the mutation (homozygous
minor allele carriers: controls: 3,33%, early onset ileal CD:
10.75%; OR 4.093, 95% CI 1.981 to 8.455, p=0.00004).
Amongst the 237 analysed patients with exclusive colonic CD
(L2) only 19 had a disease onset prior to age 18. None of these
were homozygous for the risk variant and with a MAF of 13,64%,
the SNP distribution showed no significant difference to controls
(OR 0.803, 95% CI 0.334 to 1.926, p=0.62172). We also
compared early versus late onset in ileal CD patients and found a
similar result as in the comparison with healthy controls (allele
frequency: OR 1.760, 95% CI. 1.251 to 2.477, p=0.00106;
homozygous carriers: OR 4.484, 95% CI 1.995–10.077,
p=0.00009). The mean age of onset was similar between the
CD patients in the different cohorts, as was the mean age of
controls at the time of blood sampling for later DNA extraction
(Table 3). In addition to testing for allele frequency differences and
the increased risk of homozygous carriers, we also used additive,
recessive and dominant models of inheritance to compare the
genotype distribution between controls and early onset ileal CD as
presented in Table 4.
Author Summary
Crohn’s Disease (CD) is to date incurable and is character-
ized by severe, reoccurring inflammations that can affect
different intestinal locations. The complicated and multi-
factorial pathogenesis is not completely understood but
involves disturbed epithelial barriers and immune reac-
tions against the commensal flora in genetically predis-
posed individuals. Some inherited disease mechanisms are
specific for small intestinal CD and are often connected to
impaired Paneth cells. These specialized cells are critical for
epithelial defences in the small intestine, and their most
abundant antimicrobials (HD-5 and HD-6) are primarily
diminished in patients who suffer from CD at this location.
In this context, we previously identified a primary role of
the Wnt pathway factor TCF7L2, which regulates the
expression of both these antimicrobial peptides. We have
now studied a functional mutation in the Wnt co-receptor
LRP6 that was more frequent in early onset ileal CD. It was
also associated with severe penetrating behaviour and
linked to especially low HD-5 expression in ileal CD patient
biopsies. Independently, we found that a reduced
epithelial expression likely represents an additional im-
pairment of the Wnt co-receptor in the disorder. LRP6 is a
new player in small intestinal CD and underlines the
importance of Paneth cell antimicrobial defences in the
disease pathogenesis.
LRP6 Association With Early Onset Ileal CD
PLoS Genetics | www.plosgenetics.org 2 February 2012 | Volume 8 | Issue 2 | e1002523Impaired transcriptional expression of the Paneth cell
antimicrobial peptide HD-5 in LRP6 mutated ileal CD
patients
We further studied the influence of the Ile1062Val mutation on
HD-5 mRNA expression in ileal mucosa obtained from a cohort
endoscoped in our department. To exclude influences of NOD2
defects on the transcriptional expression of HD-5 [14], individuals
with mutations in the pattern recognition receptor were excluded
from the analysis. We furthermore excluded patients with a
neoterminal ileum as a result to previous resection. Besides
confirming the general decrease of HD-5 in ileal CD patients, we
found the lowest expression of HD-5 in the ileal CD group of
LRP6 Ile1062Val mutated patients (Figure 3) which suggests a
specific relevance of the polymorphism in ileal CD. Confirming
previous data [15,16] inflammation per se did not seem to
influence HD-5 expression (Figure 3A right panel).
Diminished LRP6 mRNA levels represent an additional
impairment in ileal CD
Studying the transcriptional expression level of LRP6 in our
cohort mucosal biopsy samples, we found generally diminished
LRP6 mRNA levels in ileal CD (Figure 3B). As expected,
according to the known effect on signalling impairment -but not
expression level- [30] the reduction of LRP6 was independent
from the functional mutation. The reduced transcriptional
expression of LRP6 might be an additional factor which
contributes to the especially low levels seen in LRP6 mutated ileal
CD patients. Consistent with the latter interpretation, levels of
LRP6 showed a significant correlation with the Paneth cell
antimicrobial HD-5 in healthy controls (Figure 4A). When
analysing all samples according to the genotype we found a
significant correlation in all LRP6 wild type individuals (Figure 4B).
Interestingly, in carriers of the rare mutant allele (Figure 4B) the
correlation was absent supporting a possible direct effect of
rs2302 85. Similar to HD-5 (Figure 4A), inflammation per se did
not seem to affect LRP6 in our sample set, clearly it did not
account for the described reduction (Figure 4B). Taken together
the data suggest that both, the mutation, as well as the diminished
expression level of LRP6 contribute to the reduced levels of HD-5
in ileal CD patients.
Since HD-6, the second most abundant Paneth cell product is
also reduced in ileal CD, we additionally analysed its expression
according to the LRP6 genotype in our patients. It is known that
Figure 1. Known exonic SNPs in LRP6. (A) LRP6 gene card with locations of exonic SNPs published in the NCBI SNPdb. Variants which lead to an
amino acid exchange are marked in red. A deletion mutation causing a different protein chain is marked in blue, silent variants are marked in green.
(B) Linkage disequilibria (LD) of the exonic SNPs in CD patients of the Oxford cohort. 7 of the genotyped SNPs were not present. We conclude that
there is no significant LD between the sole coding variant (rs2302685) and any of the synonymous SNPs.
doi:10.1371/journal.pgen.1002523.g001
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PLoS Genetics | www.plosgenetics.org 5 February 2012 | Volume 8 | Issue 2 | e1002523Figure 2. Risk for rs2302685 C-allele carriers in the different disease subgroups and the influence of detailed phenotyping. A) Odds
ratios and confidence intervals for the different comparisons are shown. The frequency distribution of the minor rs2302685 allele was analysed in
different cohorts and combined samples: odds ratios and 95% confidence interval for the allele frequency are shown for patients with specific disease
subtypes of ileal CD (classified as either L1 (solely ileal) or L3 (ileal and colonic involvement)) compared to healthy control individuals. The early onset
as well as the penetrating behaviour subgroup displays an significantly increased Minor allele frequencies (MAF). B) An especially high risk for early
onset ileal CD is found for homozygous minor C - allele carriers. This becomes apparent in the high odds ratios for such individuals in the different
cohorts and combined samples (left panel) and an highly increased CC genotype frequency compared to the control samples and other disease
groups (right panel). C) The MAF distribution was analysed in different cohorts and combined samples: odds ratios and 95% confidence interval for
the MAF are shown for patients with ulcerative colitis (UC) (left panel) and CD patients with solely colonic involvement (right panel) compared to
healthy control individuals. The lack of an increase in the odds ratios for the different comparisons allows excluding major effects of the variant in the
colonic IBD subgroups.
doi:10.1371/journal.pgen.1002523.g002
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PLoS Genetics | www.plosgenetics.org 6 February 2012 | Volume 8 | Issue 2 | e1002523both Paneth cell a-defensins are regulated by the Wnt pathway, so
we expected a similar effect. As hypothesized, the two factors
showed a correlating pattern in wild type as well as in mutated
individuals in our cohort and HD-6 exhibited the same
dependence on the LRP6 genotype which was seen for HD-5 in
ileal CD (Figure 5A). We also measured lysozyme, another
antimicrobial found in Paneth cells which is not decreased in ileal
CD and also not known to be dependent on canonical Wnt. As
expected, there was no change in lysozyme mRNA levels in ileal
CD carriers of the rare LRP6 SNP compared to the wild type ileal
CD subgroup and also no correlation with HD-5 in either
subgroup.
LRP6 overexpression induces b-catenin–dependent
induction of HD-5 promoter activity
As mentioned above it is known that b-catenin dependent Wnt
signaling activity is crucial for Paneth cell maturation and that
disruption of the pathway precedes impaired Paneth cell gene
expression andfunction. Sincewe founddiminishedlevelsofPaneth
cell a-defensins in ileal CD patients carrying a coding SNP variant
in LRP6, we wanted to further analyse the Wnt co-receptor’s role in
this context. To confirm the expression of LRP6 in small intestinal
epithelia, we performed immunohistochemistry staining of the co-
receptor on ileal tissue slices from healthy controls as well as ileal
CD patients. LRP6 was found to be generally expressed in epithelial
cells of the small intestine, and also present at the very bottom of
intestinal crypts at the sites where Paneth cells as well as stem cells
reside. Interestingly, LRP6 was also sporadically detected in
infiltrating immune cells. A 406magnification of a representative
section is included in Figure 6A. To directly study the relationship
between LRP6 activity and Paneth cell HD-5, we used an in vitro
model of transiently transfected HEK293 cells. From previous work
it is known that overexpression of LRP6 is sufficient to induce b-
catenin dependent Wnt signalling activity, even without additional
stimulation with Wnt ligands or other pathway activating
compounds. As a positive control we used the Wnt responsive
TopFlash promoter (Figure 6B). Overexpression of LRP6 led to an
increase of transcriptional activity of an 1 kb HD-5 promoter
construct (Figure 6C). As expected this was not seen using a non-
functional (dominant negative) version of the co-receptor lacking
important intracellular domains which are necessary for Wnt signal
transduction.
Discussion
Complementing the previously described involvement of Wnt
TCF7L2 [24,25] in ileal Crohn’s Disease, we now report an
association of the rare coding SNP variant of rs2302685
(Ile1062Val) in the Wnt co- receptor LRP6 with early-onset ileal
CD. In addition, we found a genotype independent mucosal
reduction of LRP6 level in ileal CD tissue. From mouse models, it
is known that specific intestinal blockage of LRP6 has devastating
consequences on the regenerative and proliferative potential of
intestinal epithelia which can result in inflammation as well as
mucosal degeneration [30]. So far for LRP6, nothing has been
known about an involvement in the development of human
inflammatory bowel disorders. However, human studies could
establish that the presence of the rs2302685 rare coding variant
(C-allele) results in generally diminished signalling activity of LRP6
[31]. Since the Wnt signalling transcription factor TCF4
(TCF7L2) directly affects the transcription of HD-5 and HD-6
[25] and is genetically associated with ileal disease [24] we
hypothesized that the LRP6 mutation also affects innate antimi-
crobial Paneth cell function. Ileal CD patients who feature the C-
allele showed significantly further reduced Paneth cell defensin
expression levels in mucosal ileal tissue but unchanged levels of
lysozyme, an additional but canonical Wnt independent Paneth
cell antimicrobial. To corroborate a potential direct relationship
between LRP6 function and the transcriptional expression of HD-
5, we performed transient transfection experiments in HEK293
cells and found an induction of a 1 kb HD-5 promoter fragment
upon overexpression of LRP6 which precedes activation of b-
catenin dependent Wnt signalling.
A possible limitation of the association study could be the early
onset sample size. The overall studied cohort numbers are very
high, but only a limited fraction (,12%) of analysed ileal CD
patients shared the phenotype of early onset. However it should
be noted that the first found result could be prospectively tested
and confirmed in two additional cohorts. Other limitations might
Table 4. Overall statistical analysis in controls versus early onset ileal CD.
Controls vs early onset ileal CD Allele positivity Armitage’s trend
allele frequency homozygous risk dominant model recessive model additive model
Cv sT CC vs TT CC vs CT+TT TT vs CT+CC T common odds
Odds ratio 1.797 4.093 1.776 0.286 1.877
95% CI 1.298 to 2.487 1.981 to 8.455 1.170 to 2.696 0.142 to 0.577
p-value 0.00034 0.00004 0.00632 0.0002 0.00033
Bonferroni adjusted p-value 0.00374 0.00044 0.06952 0.0022 0.00363
The genotypes for which the risk was calculated are marked in bold. The Bonferroni adjusted p-values were calculated with regards to all comparisons in the overall
sample group (adjusted for 11 tests).
doi:10.1371/journal.pgen.1002523.t004
Table 3. Age of included individuals.
Mean age at sampling Mean age at onset
Controls Ileal CD (L1+L3) Colonic CD (L2)
Oxford 42.69 (614.62) 27.46 (611.79) 34.03 (614.71)
Leuven 35.00 (617.30) 30.33 (611.16) 31.97 (611.18)
Vienna 36,73 (611.99) 27.89 (69.39) 28,07 (610,12)
Provided are the mean age 6 standard deviation. For controls we listed the age
at time of DNA sampling, for CD patients we provide the mean age at onset.
doi:10.1371/journal.pgen.1002523.t003
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PLoS Genetics | www.plosgenetics.org 7 February 2012 | Volume 8 | Issue 2 | e1002523apply to the mucosal tissue expression studies. For assessing
genotype-depending expression levels we had no intestinal tissue
from homozygous C-allele carriers and we only could test tissue
from adult patients. Both factors are due to restricted biopsy
material resources. A potentially even stronger effect in
homozygous C-allele carriers or a cause-effect-relationship in
paediatric ileal CD remains therefore to be investigated. Since
healthy controls featuring the C-allele heterozygously showed
almost normal levels of HD-5, it is clear that other factors must
be involved, especially to explain the specific effect of the
mutation in ileal CD patients. Patients who carry the rare variant
might only in combination with other underlying disturbances be
prone to an early symptom development. It is quite conceivable
that these could be the same mechanisms which explain
diminished HD-5 expression in ileal CD in general. The
combination of different defects, including the mutation in
LRP6, might add up to the strong decrease of HD-5 and HD-6
which is specifically seen in this subgroup. One potential additive
mechanism could be the diminished transcriptional expression of
LRP6, which was seen independently from the patient’s
genotype. However, the mechanisms explaining reduced LRP6
expression still needs to be determined. In addition to LRP6, the
described decrease of TCF4 (TCF7L2) and this Wnt transcription
factor is likely another additive mechanism [15,24,32]. To
analyse such potentially additive functions of the reported
impairments in canonical Wnt should be the aim of future
investigations. Most previously identified Crohn’s disease loci
[33,34] are common to both early and later disease onset.
Exclusive early onset disease associated variants are extremely
rare and none are known for the ileal version specifically. An IL-6
promoter SNP was recently associated with early onset CD in
general but confined solely to male patients [35]. Five novel
genomic regions were additionally associated with general early-
onset IBD in a genome wide association study, including 16p11
near IL27 [34]. The identification of rs2302685 as an ileal early
onset and also penetrating CD risk variant potentially provides a
first location specific diagnostic marker for such high risk
individuals.
Figure 3. mRNA expression in ileal CD: Effect of the coding rare rs2302685 variant on the expression levels of HD-5 and LRP6. We
excluded individuals with mutations in the pattern recognition receptor NOD2 as well as patients with a neoterminal ileum. All cohort samples were
sub-grouped according to the disease state and analysed with respect to the LRP6 genotype. A) As previously reported, HD-5 mRNA levels are
diminished in ileal CD as compared to controls and colonic CD. We saw no difference between ileal CD samples that came from inflamed tissue at the
time of biopsy taking and material from 6 uninflamed biopsy specimens (left panel). The mRNA expression of HD-5 seems to be influenced by the
coding rare LRP6 rs2302685 allele (C- allele) in ileal CD patients as carriers of the variant show the lowest HD-5 levels. B) Similar to the diminished HD-
5, we found significantly decreased LRP6 transcriptional expression in ileal CD patients as compared to controls as well as to patients with exclusive
colonic CD. Again similar to HD-5, we found no difference between inflamed compared to uninflamed ileal CD samples. The presence of the
functional LRP6 mutation however, seems to have, as expected, no effect on LRP6 mRNA level.
doi:10.1371/journal.pgen.1002523.g003
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PLoS Genetics | www.plosgenetics.org 8 February 2012 | Volume 8 | Issue 2 | e1002523Other studies on LRP6 genetic variances have so far been done
in the context of variability in bone mass density, bone disorders
[36], late-onset Alzheimer’s disease [31], macular degeneration
[37] and cardiovascular diseases [38,39]. Complications affecting
the bone are frequent in IBD with disease-inherent factors
appearing to confer a risk irrespective of corticosteroid treatment.
The newly reported genetic association of LRP6 might contribute
to the occurrence of such extraintestinal manifestations but further
studies are required to analyse a potential role in detail. Finally, it
is important to acknowledge the context of the LRP6 association as
it provides further evidence for the significance of the Paneth cell
in the development of small intestinal CD. Multiple genetic CD
variants have already been specifically associated with small
intestinal involvement and most of the involved genes are
important in the specialized cell’s biology [7]: the Wnt
transcription factor TCF7L2 [24], NOD2 [23,40], ATG16L1
[41,42], XBP1 [43] and very recently the potassium intermedi-
ate/small conductance calcium-activated channel KCNN4 [44].
Figure 4. Correlation of HD-5 and LRP6. Linear regression and Spearman rank analysis were used on all samples from the mRNA analysis. The
samples were grouped according to A) their disease state (diseased mucosa or non-inflamed mucosa of patients) as well as in all samples B)
according to the LRP6 genotype. Interestingly the two factors exhibit a correlating pattern in controls (independent of the genotype) as well as in all
wild type samples but not in the C-allele carrying individuals.
doi:10.1371/journal.pgen.1002523.g004
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PLoS Genetics | www.plosgenetics.org 9 February 2012 | Volume 8 | Issue 2 | e1002523The co-receptor LRP6 may now be added as a novel player in
early onset and penetrating behaviour in ileal CD. The multiple
genes linked to ileal CD support the concept that impaired Paneth
cell antimicrobial function represents a primary and a not
secondary defect [45,46]. Most importantly, it provides an
attractive and direct therapeutic target [47] as an alternative to
the current merely anti-inflammatory approaches in Crohn’s
disease therapy.
Methods
Patients
All patients and healthy controls included in the present studies
gave their written and informed consent after the study purpose,
sample procedure, and potential adjunctive risks were clarified. All
studies were approved by the ethics committees of the Medical
University Vienna, Austria, the University Hospital Tu ¨bingen,
Germany, the University of Leuven, Belgium and the Oxford
Radcliffe Hospital Trust, Great Britain. Sub-grouping of included
patients was done according to phenotype data which was based
on clinical, radiological, endoscopic and histopathological diagno-
ses at the respective IBD centres (Figure S1). For genetic analysis,
we evaluated 3 DNA cohorts (all of Western European descent) of
CD and UC patients as well as healthy unrelated controls [24].
For the genetic study we included all definitely phenotyped
patients, the cohorts also include patients who underwent surgery
(colectomy in UC, or ileocolonic resection in CD), those with an
additional involvement of the upper gastrointestinal tract (Mon-
treal +L4) as well as patients with perianal disease. We did not
further subgroup the cohorts according to these criteria as we
focussed our analysis on disease location, behaviour and age of
onset. Biopsies and blood were additionally collected from patients
and controls in Stuttgart; in this cohort, NOD2 mutant individuals
as well as patients with a neoterminal ileum (after ileocecal
resection) were excluded to avoid an mRNA effect bias. We
included biopsies of healthy controls and patients with and without
active inflammation and also stratified the cohort according to this
criterion. In line with the Montreal classification three CD
subgroups were defined to accommodate the different disease
locations: ileal disease only (L1), colonic disease only (L2) and
ileocolonic disease (L3).
Candidate gene approach and SNP selection
We included all exonic LRP6 SNPs which were documented in
the NCBI SNPdb (Genotype and allele frequency build 129). DNA
was isolated by standard procedures. Multiplex genotyping was
performed with the MassARRAY Compact System from Seque-
nom (San Diego, USA) [24].
LRP6 genotyping
All primers were designed using reference sequences as denoted
by the NCBI SNPdb and Sequenom software (San Diego, USA)
and are provided in Table S1. All materials originated from the
Sequenom iPLEX Gold Kit and were used according to the
manufacturer’s protocol (Sequenom). The applied MALDI-TOF
MS based SNP genotyping method measures the time of flight of
ionized molecules to determine their masses. Respective fragments
(,100 bp including the SNP) for our analysis were assembled via
Multiplex-PCR and verified using gelelectrophoresis. After a
Shrimp Alkaline Phosphatase (SAP) clean- up procedure, a specific
Figure 5. HD-6 but not lysozyme is reduced in patients who carry the rare LRP6 variant. Linear regression and Spearman rank analysis
were used on all samples from the mRNA analysis according to the LRP6 genotype. (A) The two Paneth cell a-defensins correlate in both subgroups
fitting the also found genotype dependent decrease of HD-6 in ileal CD patients. This, as well as the independence from inflammation matches the
pattern seen for HD-5. (B) Lysozyme on the other hand does not correlate with HD-5 and seems to be uninfluenced by the LRP6 genotype in ileal CD.
doi:10.1371/journal.pgen.1002523.g005
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PLoS Genetics | www.plosgenetics.org 10 February 2012 | Volume 8 | Issue 2 | e1002523linear primer extension (PEX) reaction was performed creating
genotype specific products with distinguishable masses. A cleanup
step with Resin (exchange of cations) for optimizing mass
spectrometry analysis of the extended reaction products was
performed before the samples were loaded and analysed.
NOD2 mutation analysis
Genotyping for the relevant NOD2 mutations was performed in
patient samples using TaqMan technology (Applied Biosystems,
Foster City, California, USA), as previously described [14].
Real-time PCR
1 ml of total RNA isolated from snap frozen ileal tissue biopsies
were checked for quality before transcribed into cDNA using oligo
(dT) primers and the AMV- reverse transcriptase (RT) kit
according to the manufacturer’s protocol (Promega). Real-time
PCR with cDNA corresponding to 10 ng total RNA was
subsequently performed with a LightCycler 480 (Roche Diagnos-
tics, Mannheim, Germany) using materials from the LightCycler
480 SYBR Green I Master kit according to the manufacturer’s
protocol (Roche). Specific plasmid standards for the selected
products were utilized to calculate exact copy numbers and
primers are provided in Table S2.
Cell culture
HD-5 luciferase reporter constructs have been kindly provided
by Be ´atrice Romagnolo and Pauline Andreu (previously described
by [48]). LRP6 expression plasmids were gratefully received from
Xi He and Mikhail V. Semenov (previously described by [49,50]).
Vladimir Korinek kindly provided us with the Wnt responsive
TopFlash luciferase reporter construct [51]. HEK293 cells in 24-
well plates were transfected with 200 ng of the full-length LRP6
expressing vector, a non-functioning dnLRP6 expressing vector, or
an empty vector, together with 200 ng of a TopFlash luciferase or
HD-5 promoter construct and 50 ng of a Renilla luciferase
expressing vector in each well using the FuGENE 6 reagent
(Roche) according to the manufacturer’s protocol. The luciferase
activity was measured after 48 hours via the Dual Luciferase
Reporter Assay System (Promega). Firefly luciferase activity
corresponding to the studied promoter constructs was normalized
Figure 6. Increased activity of b-catenin–dependent Wnt via overexpression of LRP6 transactivates human a-defensin 5 promoter
activity in HEK-293 cells. As demonstrated with immunohistochemistry staining A), the Wnt co-receptor LRP6 is widely expressed in the cells of
the small intestinal epithelium and also found at the base of the crypts where Paneth and stem cells are located. Additionally, LRP6 is sporadically
found in infiltrating immune cells. As previously demonstrated, overexpression of LRP6 in HEK293 cells leads to an activation of b-catenin dependent
Wnt signalling B) as monitored by TopFlash activity. The transcriptional activity of a luciferase reporter under the control of an 1 kb HD-5 promoter
was also increased after LRP6 mediated activation of Wnt C). Both effects were not seen using a non-functional version of the LRP6 Co-receptor which
is lacking cytoplasmatic parts that are necessary for signal transduction. Values are the average of triple determinations with the SEM indicated by
error bars.
doi:10.1371/journal.pgen.1002523.g006
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PLoS Genetics | www.plosgenetics.org 11 February 2012 | Volume 8 | Issue 2 | e1002523with respect to transfection efficiencies using the respective activity
of the co-transfected Renilla luciferase. Transfections were carried
out in triplicates and 4 independent experiments were performed.
Immunohistochemistry
Immunostaining for LRP6 was performed using a two-step
immunoperoxidase technique (EnVisionTM, Dako, Glostrup,
Denmark) as described previously [52]. Slides were heated for
30 minutes in a steamer for antigen retrieval (pH 9) and incubated
for 1 hour with the primary anti-LRP6 antibody (ABGENT, San
Diego, USA) diluted 1:100 in TBST (20 mM Tris-Base (pH 7.4),
0.14 M NaCl, 0.1% Tween 20). LPR6 protein was visualized by a
horse-radish-peroxidase (HRP)-labelled secondary antibody
(Dako) which was detected with 39-diaminobenzidine tetrahy-
drochloride (Dako). Slides were counterstained with hematoxylin.
Computer analysis and statistics
mRNA levels were normalized to b- actin and evaluated by
GraphPad Prism Ver. 5.0. To analyse the effect of Ile1062Val
between the groups, as well as the cell culture experiments, we
performed the non- parametric statistical Wilcoxon-Mann-Whit-
ney-Test. Spearmen rank analysis was used to test for correlation.
For genetic analysis we used Finetti specialized software (http://
ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl). Linkage dis-
equilibria and haplotype blocks were calculated with Haploview.
To avoid statistical bias due to multiple testing between different
subgroup in the overall association analysis, we calculated
Bonferroni adjusted p-values for the comparison between early
onset ileal CD and controls.
Supporting Information
Figure S1 Overview of the work flow. The association study was
carried out within 3 previously assembled IBD DNA cohorts in a
retrospective way. DNA and biopsies from patients and controls
for the mRNA study and immunohistochemistry were additionally
collected at the Robert Bosch hospital in Stuttgart.
(TIF)
Table S1 Genotyping Primers: Oligonucleotides used for
multiplex PCR approaches are termed 1
st- respectively 2
nd-PCRP.
Primers used for genotype specific elongation are termed PEXP.
(DOCX)
Table S2 Real-time PCR Primers: Oligonucleotides which were
used for the creation of standards and mRNA quantification.
(DOCX)
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